Skip to main content
Premium Trial:

Request an Annual Quote

Lynx Completes Funding Round to Develop Sequencing Technology


HAYWARD, Calif.--Lynx Therapeutics here has completed a $26.8 million private placement of common stock at $10 per share. Proceeds will go toward finishing development of the company's proprietary Massively Parallel Signature Sequencing technology and building capacity for its early commercial uses. Completion of the financing "predated by a few weeks the first results ever obtained from application of the technology to a real biological system," noted Sam Eletr, Lynx's chairman and CEO.

"These results showed that, even in its very early stages of development, Lynx's technology may well enable the identification of unknown genes, as well as uncover otherwise inaccessible details of gene expression," he continued. "The financing will speed up not only the technology's development, but also, and perhaps more importantly, its early application to a broad spectrum of important biological problems."

Massively Parallel Signature Sequencing technology aims to iden tify short signature sequences from a million or more DNA molecules or fragments at once. Lynx is developing the technology for a number of applications, including gene identification, gene expression profiling, pathogenic genome se quencing, and very high resolution genomic mapping. Founded in 1992, the company has 71 employees.

Filed under

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.